Lipid nanoparticles (LNPs) are self-assembled colloidal structures held together by weak, non-covalent interactions between ionizable lipids, helper lipids, cholesterol, and PEG-lipids. Once an LNP leaves the manufacturing environment, it begins to respond to whatever stresses the next step imposes — temperature shifts during storage, freeze–thaw transitions before use, ionic and protein challenges upon dilution into culture medium, and the enzymatic, acidic, and serum-rich environment of the cell culture well. Each of these steps can shift the LNP away from its freshly prepared state, and almost any such shift has the potential to erode the transfection efficiency that the formulation was originally designed to deliver. For scientists running transfection studies, stability is not an abstract quality attribute — it is the variable that determines whether the data generated today is comparable to the data generated last month, and whether the formulation that worked in the discovery screen will still work when prepared fresh by a colleague next quarter.
The challenge is that LNP stability is multidimensional. A formulation can hold its hydrodynamic diameter and zeta potential beautifully for nine months at 4 °C and yet lose half of its transfection potency in the same window because of lipid oxidation, ionizable lipid rearrangement, or payload degradation. Equally, a freshly thawed sample can pass every physical test yet deliver poor transfection because the dilution buffer pushed the surface charge into a range that destabilized the colloidal suspension before the cells ever saw the LNP. This is why a meaningful LNP stability program for transfection studies cannot rely on a single test. It must follow the LNP through every stage of its lifecycle — from the storage vial, through thawing and handling, through working-solution preparation, and finally through the cell culture incubation — and it must apply at each stage the analytical methods that are sensitive to the failure modes specific to that stage.
In storage, LNPs sit in concentrated form — typically 0.5 to 5 mg/mL total lipid in cryovials or sealed glass containers — within a defined buffer system (commonly Tris or PBS with cryoprotectant). The particles are far enough apart that inter-particle collision is rare, and the chemical environment is stable. The failure modes at this stage are primarily slow and chemical: ionizable lipid oxidation to aldehydes and peroxides, hydrolysis of ester bonds in the helper or PEG-lipid, mRNA depurination or backbone cleavage, subtle shifts in pH, and gradual PEG-lipid desorption from the surface. Physical aggregation is usually a late-stage symptom that emerges only after months of chemical destabilization, except when a missed cryoprotectant or repeated freeze–thaw exposure during inventory pulls accelerates the process.
For scientists building a stability program around lipid nanoparticle stability, the storage stage is where shelf-life claims are generated, where batch-to-batch consistency is verified, and where the early-warning signals for downstream failures appear. Because changes here propagate forward, every observation recorded in storage — drift in particle size, drop in encapsulation efficiency, shift in pKa — has the potential to explain a transfection surprise months later.
A storage stability panel needs to be both broad and economical, because most lots will be tested multiple times across multiple time points. The minimum recommended panel combines four orthogonal techniques that cover the dominant failure modes.
Particle size and size distribution (DLS or NTA): Dynamic light scattering remains the workhorse for storage stability, typically performed via nanoparticle size analysis on a Malvern Zetasizer or equivalent. For a well-formulated LNP, the z-average diameter should remain within ±10 nm of the day-0 value and the PDI should stay below 0.2 across the storage window. NTA complements DLS by detecting subpopulations of larger aggregates that DLS underestimates, and is particularly valuable when long-term stability is being claimed.
Zeta potential and surface charge: Zeta potential is measured by electrophoretic light scattering. For LNPs that will be stored near physiological pH, the typical accepted range is roughly −10 to +5 mV when the surface PEG-lipid shield is intact. Drift beyond ±5 mV from the day-0 value suggests PEG-lipid desorption or surface rearrangement. Nanoparticle zeta potential analysis run in parallel with size analysis gives a complete physical picture of the LNP surface.
Encapsulation efficiency by RiboGreen or PicoGreen: Encapsulation efficiency (EE%) is the most sensitive early indicator of payload loss. The RiboGreen assay compares total RNA signal (with detergent) to free RNA signal (without detergent), and an EE% drop of more than 5–10% from the day-0 value is generally considered a stability concern. For DNA payloads, PicoGreen is the equivalent. EE% must remain stable alongside size and charge — if size is stable but EE% drops, the LNP is leaking cargo without visibly aggregating, a particularly insidious failure mode for transfection.
Lipid integrity by RP-HPLC or LC-MS: Lipid hydrolysis and oxidation can be detected by reversed-phase HPLC with charged aerosol or evaporative light scattering detection. The ratio of intact lipid to its hydrolysis or oxidation products is reported as a purity percentage. For ionizable lipids, the appearance of aldehyde impurities — measurable using the fluorogenic NBD-H reagent — correlates strongly with downstream mRNA adduct formation. This is the level at which LNP critical quality attributes and QC testing becomes essential for any program that expects to use stored material to generate comparable transfection data.
Optional: payload integrity by capillary electrophoresis: For mRNA-LNPs, an Agilent Bioanalyzer or Fragment Analyzer trace of the extracted payload shows whether the mRNA has degraded to lower-molecular-weight fragments. For siRNA and other shorter payloads, denaturing PAGE or chip-based electrophoresis is sufficient. Payload integrity matters because a leaky LNP can still register an acceptable EE% even when the encapsulated RNA is already fragmented beyond functionality.
Four variables dominate the storage stability profile. Temperature is the most impactful: −80 °C storage with appropriate cryoprotectant (typically sucrose or trehalose at 5–10% w/v) generally gives the best long-term outcomes; 2–8 °C storage is acceptable for short-term (1–2 week) use but accelerates hydrolysis; 25 °C storage is useful as an accelerated condition but typically shows measurable degradation within 1–4 weeks. Buffer composition — pH, ionic strength, and the presence of chelators or antioxidants — can shift the hydrolysis and oxidation kinetics by an order of magnitude. Tris-based buffers generally outperform PBS at frozen temperatures because PBS undergoes large pH shifts during freezing. Duration must be matched to the program need: short-term stability supports single-batch screening, while long-term stability is needed for cross-cell comparability and clinical translation. Freeze–thaw cycles are the single most damaging routine event, and even a single cycle without cryoprotectant can shift the size distribution and aggregation profile.
Table 1. Recommended Storage-Stage Stability Panel — Tests, Targets, and Typical Acceptable Ranges.
| Test | What It Detects | Typical Acceptable Range | Inquiry |
| Hydrodynamic size (DLS) | Aggregation, fusion, swelling | z-average within ±10 nm of day-0; PDI < 0.2 | Inquiry |
| Zeta potential | Surface rearrangement, PEG-lipid desorption | −10 to +5 mV at pH 7.4; drift < 5 mV | Inquiry |
| Encapsulation efficiency (RiboGreen/PicoGreen) | Cargo leakage | EE% drop < 5–10% from day-0 | Inquiry |
| Lipid purity (HPLC/LC-MS) | Hydrolysis, oxidation, aldehyde impurities | Lipid purity > 95%; aldehyde below threshold | Inquiry |
| Payload integrity (CE/Bioanalyzer) | mRNA/siRNA fragmentation | Main peak > 70–80% of total | Inquiry |
BOC Sciences designs time-point-based storage stability protocols tailored to your LNP composition, payload, and target shelf-life, with full orthogonal testing across size, charge, encapsulation, lipid, and payload attributes.
The pre-use window begins when the LNP vial is removed from its storage condition and ends when it is diluted into the working solution. It is a short, intense interval during which the LNP is exposed to thawing, transient temperature swings, light exposure, air contact, and the first mechanical stresses of pipetting and vortexing. For frozen material, the thawing step is the largest single perturbation in the entire workflow: ice crystals can disrupt the bilayer, the cryoprotectant may be insufficient to prevent fusion, and the rapid temperature transition can drive lipid phase changes that are not fully reversible. For lyophilized material, the reconstitution step introduces an additional variable — the choice of reconstitution solvent can swell or contract the LNP depending on its polarity and tonicity. Lipid nanoparticle characterization performed at this stage acts as a release test, confirming that the material still meets the day-0 specification before any transfection reagents are prepared.
The pre-use test panel is intentionally compact: it needs to be fast enough to be performed immediately before each transfection experiment, yet sensitive enough to catch the most common pre-use failures.
Visual inspection: Hold the vial against a white and a dark background under good lighting. A clear, slightly opalescent solution is the expected appearance for most LNPs. Visible cloudiness, particulates, or phase separation indicates aggregation or precipitation and the vial should be discarded. For dye-labeled or fluorescent LNPs, color consistency can also be checked at this step.
Post-thaw size by DLS: Run a quick DLS measurement immediately after thawing or reconstitution. The z-average diameter and PDI should fall within the same range observed at the storage release. A PDI shift of more than 0.05 or a z-average increase of more than 10 nm compared with the day-0 measurement is a strong signal that the thaw or reconstitution has damaged the formulation. LNP cryoprotectant screening services can be applied to formulations that fail this test repeatedly, to identify a cryoprotectant that better preserves the colloidal state through freeze–thaw.
Encapsulation efficiency spot check: A quick RiboGreen or PicoGreen read on a small aliquot confirms that the thaw did not cause cargo leakage. This measurement can be combined with the DLS measurement to save sample. Efficiency testing for LNP encapsulation at this stage is particularly valuable when working with previously opened vials, where evaporation, pH shift, or contamination from repeated pipetting can compromise the cargo retention.
Payload integrity by rapid CE or gel: For mRNA payloads, a Bioanalyzer or Fragment Analyzer run takes about 30 minutes and provides the most direct evidence of whether the cargo is still translationally competent. For siRNA and DNA, a 15% TBE-urea gel or agarose gel respectively is sufficient. Payload retention testing for LNP encapsulation is recommended whenever the same vial will be used across multiple transfection experiments, since each freeze–thaw or storage pause can accumulate damage.
Three variables define the pre-use window. Mixing intensity must be gentle — vortexing at high speed can shear LNPs and drive aggregation; gentle flick-mixing or short low-speed vortexing is preferred. Hold time on the benchtop matters: LNPs thawed but not used within 2–4 hours at room temperature can begin to lose integrity, particularly if the buffer does not contain chelators or antioxidants. Working concentration during this window should not be lower than approximately 0.1 mg/mL total lipid; highly diluted pre-use samples can aggregate because the inter-particle distance is no longer sufficient to prevent collision-driven fusion.
Table 2. Recommended Pre-Use Stage Release Panel.
| Test | What It Detects | Acceptance Criterion | Inquiry |
| Visual inspection | Visible aggregation, precipitation | Clear, no particulates, opalescent normal | Inquiry |
| Post-thaw size (DLS) | Freeze–thaw damage, fusion | z-average within ±10 nm of day-0; PDI < 0.2 | Inquiry |
| Encapsulation efficiency (RiboGreen) | Cargo leakage during thaw/handling | EE% drop < 5% from day-0 | Inquiry |
| Payload integrity (CE/gel) | RNA/DNA degradation | Main peak > 70% of total signal | Inquiry |
BOC Sciences supports pre-use release testing with rapid DLS, EE%, and payload integrity checks that catch thaw and handling damage before the LNP enters the transfection experiment.
When the LNP stock is diluted into serum-containing or serum-free culture medium to reach the working concentration, the colloidal environment changes abruptly. The ionic strength rises, the pH shifts to the buffered medium value, serum proteins begin to adsorb onto the LNP surface forming a protein corona, and the inter-particle distance shrinks by orders of magnitude as concentration drops. This is the stage at which many "stable in the vial" formulations first reveal their weaknesses. The protein corona can mask the targeting ligand, change the effective surface charge, and in some cases promote aggregation via bridging. The dilution buffer can also drive rapid cargo leakage if it shifts the LNP away from the pH range that stabilizes the protonated ionizable-lipid–nucleic acid complex.
For LNP buffer screening, the goal is to identify a dilution environment that preserves the colloidal state and minimizes protein-corona-driven aggregation. For pDNA or mRNA-LNPs formulated in low-pH buffers, dilution into neutral culture medium can transiently deprotonate the ionizable lipid and allow cargo to diffuse out — a phenomenon that is most visible as an EE% drop measured immediately after the dilution.
The dilution-stage panel tests the LNP in the exact buffer and concentration that will be applied to the cells. Running the same panel in the stock buffer is not informative — the LNP must be measured in the stressed state.
Particle size and concentration after dilution (NTA preferred): NTA is generally more accurate than DLS at low concentrations, because the LNP count is too low for DLS to give a reliable z-average. It also reports particle concentration directly, which DLS cannot. The size distribution should remain unimodal with no new peaks above 200 nm. NTA also detects subvisible aggregates that DLS misses. Nanoparticle drug loading analysis using the same diluted sample can be combined to give size and EE% in one workflow.
Zeta potential in the diluted medium: Measure zeta potential in the actual diluted medium rather than in water. Serum proteins shift the effective charge — a formulation that reads −5 mV in water may read −12 mV in 10% serum. The drift from the day-0 value is more meaningful than the absolute reading, but |zeta| > 25 mV is generally a flag for colloidal instability. Nanoparticle surface charge analysis at this stage helps diagnose whether the protein corona is forming as expected or whether the formulation is being destabilized by the new environment.
Encapsulation efficiency in the diluted sample: Run the RiboGreen or PicoGreen assay directly on the diluted sample, not on the stock. A significant EE% drop measured after dilution is direct evidence of cargo leakage driven by the buffer change. This is one of the most important measurements for understanding transfection variability across different cell lines or media formulations.
Cryo-EM snapshot for morphology change: For lead candidates where the dilution behavior is critical, a cryo-EM image of the diluted LNP confirms whether the particles remain as discrete dense cores or have begun to form blebs, fused structures, or amorphous aggregates. LNP excipient screening services can be paired with this measurement to identify additives (Poloxamer 188, sucrose, trehalose) that suppress dilution-induced aggregation.
Four variables dominate the dilution stage. Medium composition — DMEM, RPMI, Opti-MEM — affects ionic strength, glucose content, and buffer capacity, all of which shift the colloidal environment. Serum percentage determines the protein corona: 10% serum is standard for most transfection workflows, but serum-free transfection (Opti-MEM + supplement) is used when the protein corona would interfere with the delivery biology. Dose — typically expressed as ng of nucleic acid per well — sets the working LNP concentration and therefore the inter-particle distance; doses below approximately 10 ng/well in 96-well format can leave the LNP too dilute to remain colloidally stable. Timing — how long the LNP sits in the diluted medium before being added to cells — matters because serum protein adsorption is largely complete within 5–10 minutes but cargo leakage continues over hours.
Table 3. Recommended Dilution-Stage Stability Panel — Run in Working Medium and Concentration.
| Test | What It Detects | Acceptance Criterion | Inquiry |
| NTA size and concentration (diluted) | Aggregation, particle loss at low concentration | Mean diameter within ±15 nm of stock; concentration recovery > 80% | Inquiry |
| Zeta potential in medium | Protein corona formation, surface rearrangement | |Zeta| < 25 mV; drift < 8 mV from stock | Inquiry |
| Encapsulation efficiency post-dilution | Cargo leakage from buffer shift | EE% drop < 5% from stock value | Inquiry |
| Cryo-EM morphology (lead candidates) | Fused or amorphous structures | Discrete dense cores, no fusion products | Inquiry |
BOC Sciences evaluates dilution-stage stability in the actual working medium and dose, supporting buffer, serum, and excipient screening to identify conditions that preserve LNP integrity from vial to well.
During the incubation stage the LNP sits in culture medium at 37 °C in 5% CO2, in contact with serum proteins and living cells. It is exposed to the lowest colloidal stability conditions of the entire workflow. The ionic strength is high, the pH is buffered near 7.4, the temperature is near the lipid phase transition temperature for many formulations, and serum proteins continuously exchange on and off the LNP surface. Endonucleases in the serum can degrade any cargo that has leaked from the LNP. The cells themselves internalize a fraction of the LNPvia ApoE adsorption, LDLR-mediated uptake, or macropinocytosis, removing particles from the medium and creating a concentration gradient that drives further LNP–cell contact. Over a 4–24 hour incubation, the LNP experiences a continuous, biologically active stress that no in vitro test fully reproduces.
From a stability perspective, this stage is fundamentally about linking the upstream physical and chemical measurements to the final functional readout — transfection efficiency. An LNP that passes every pre-use and dilution test can still fail at this stage because of a subtle endosomal escape deficit, because the protein corona formed in this specific medium masks the targeting ligand, or because the ionizable lipid's protonation behavior at endosomal pH does not match the cell line's endosomal acidification kinetics. This is why the incubation-stage stability panel is necessarily more biological than the previous stages.
Medium-recovery DLS or NTA at incubation endpoint: Aspirate the cell culture supernatant at the end of the incubation period and measure particle size and concentration. This measurement tells you how much LNP remains in solution at the end of the experiment — a sharp drop indicates cellular uptake or aggregation. Comparing the recovered concentration to the initial concentration gives an apparent uptake fraction. Nanoparticle cellular uptake testing by flow cytometry on the cell layer provides the same information as a quantitative dose-response on a per-cell basis.
Reporter transfection assay: The transfection efficiency assay — most commonly luciferase luminescence, EGFP fluorescence, or β-galactosidase colorimetry — is the most important functional readout in the entire stability program. It integrates every stability-related variable from storage to incubation and converts them into a single number that can be tracked across batches and time points. For comparative stability profiling, firefly luciferase offers the widest linear dynamic range; for cell-line-by-cell-line comparisons, flow cytometry-based EGFP quantification is more informative. LNP transfection troubleshooting services can be applied when the reporter readout drops without an obvious upstream cause.
Confocal colocalization for endosomal escape: Confocal microscopy with a fluorescent cargo (Cy5-mRNA, FAM-siRNA, or fluorescently labeled lipid) and a lysosomal marker (LysoTracker, LAMP1 antibody) gives a per-cell readout of whether the cargo has escaped the endosome or remains trapped. The Manders colocalization coefficient between cargo and lysosome is a quantitative stability-and-delivery metric. Nanoparticle intracellular localization detection is the formal service equivalent of this measurement and can be combined with endosomal-escape scoring.
Galectin-8/3 recruitment assay for membrane disruption: Galectin-8 (or galectin-3) recruitment to the endosomal membrane is a sensitive marker of LNP-induced endosomal disruption. Cells expressing GFP-galectin-8 show distinct puncta when the LNP destabilizes the endosomal membrane. LNP endosomal escape evaluation combines this with functional cargo release to give a complete picture of the intracellular delivery efficiency.
Four variables dominate the incubation stage. Temperature is fixed at 37 °C for most mammalian cell transfection workflows, but reduced-temperature shifts (e.g., 4 °C for the first hour) are used in mechanistic studies to distinguish between energy-dependent and passive uptake pathways. Time — typically 4, 6, 12, or 24 hours — sets the window over which uptake, endosomal escape, and cargo release occur; shorter windows favor kinetics studies, longer windows favor steady-state reporter expression. Cell line profoundly affects stability behavior: highly phagocytic cell lines (RAW264.7, BMDCs) consume LNPs rapidly, while non-phagocytic lines (Jurkat, primary T cells) rely entirely on receptor-mediated uptake. Dose — the amount of LNP per well — sets the working concentration in the well and is the most common cause of cytotoxicity in transfection experiments; doses above 200 ng/well in 96-well format often show measurable toxicity, especially with ionizable-lipid-rich formulations.
Table 4. Recommended Incubation-Stage Stability Panel — Biological and Functional Tests.
| Test | What It Detects | Acceptance Criterion | Inquiry |
| Medium-recovery NTA at endpoint | LNP depletion by uptake or aggregation | Recovered concentration > 30–50% of input | Inquiry |
| Reporter transfection (luc/EGFP) | Functional transfection efficiency | ≥80% of fresh-control RLU or %GFP+ | Inquiry |
| Cellular uptake by flow cytometry | Particle internalization per cell | Dose-dependent MFI increase; > 70% positive cells at optimal dose | Inquiry |
| Endosomal escape (galectin/LysoTracker) | Endosomal disruption and cargo release | Cargo/lysosome colocalization < 0.4 | Inquiry |
BOC Sciences combines cellular uptake, endosomal escape, and reporter transfection assays across multiple cell lines and doses to directly connect your LNP's stability profile to its functional performance.
A stability program that follows the LNP through every stage of the transfection workflow produces data that is interpretable, comparable, and actionable. BOC Sciences provides integrated support across all four stages, anchored in orthogonal physicochemical characterization and functional transfection evaluation, with formulation optimization feedback loops that translate stability findings into improved LNP design.
BOC Sciences designs stage-appropriate stability protocols covering long-term and accelerated storage, controlled freeze–thaw, dilution stress, and incubation in biological media. Each protocol is tailored to the LNP composition (ionizable lipid identity, payload type, buffer system) and to the program's decision-making needs (release, comparability, or shelf-life claim). Our teams work with clients to define acceptance criteria, sampling intervals, and orthogonal testing panels that match the LNP's known failure modes. Lipid nanoparticle formulation support ensures that the formulation tested is the formulation intended for use.
BOC Sciences delivers the full panel of physicochemical tests described in this article, including DLS, NTA, zeta potential, encapsulation efficiency by Ribogreen/PicoGreen, payload integrity by capillary electrophoresis and Bioanalyzer, lipid purity by RP-HPLC and LC-MS, and morphology by nanoparticle morphology characterization using cryo-EM. Cryo-EM is particularly valuable for identifying subtle morphological changes that are invisible to ensemble light-scattering methods but have measurable functional consequences.
Transfection is the ultimate stability test, and BOC Sciences offers complete cell-based evaluation pipelines spanning reporter assays (luciferase, EGFP, β-gal), dose-response profiling, cell-line screening, cellular uptake quantification, endosomal escape scoring, and intracellular localization. Nanoparticle in vitro evaluation services integrate physicochemical and biological data to give a single, cohesive stability profile for each LNP. When stability data point toward a delivery deficit, LNP safety assessment services can confirm whether the formulation is also showing tolerance concerns at the relevant dose range.
Stability data without a feedback loop to formulation is descriptive only. BOC Sciences closes the loop by feeding stability findings into LNP process optimization, ionizable lipid optimization, and LNP encapsulation efficiency optimization workflows. When a stability failure mode is identified — say, dilution-driven EE% loss — the team can iterate on buffer composition, excipient screen, or ionizable-lipid selection in the next round of formulation, with stability re-testing to confirm the improvement.
Table 5. BOC Sciences Service-Lineup for LNP Stability and Transfection Studies.
| Service | Scope of Work | Key Deliverables | Inquiry |
| Storage Stability Analysis | Long- and short-term stability studies across temperatures, buffers, and time points; orthogonal size, charge, EE%, lipid, and payload panel | Time-point data package; shelf-life recommendation | Inquiry |
| Pre-Use Release Testing | Thaw/reconstitution impact; visual, size, EE%, and payload integrity checks immediately before transfection | Release report with pass/fail against acceptance criteria | Inquiry |
| Dilution Stability Evaluation | Stability in working medium at working concentration; buffer, serum, and excipient screening | Medium-specific stability profile; recommended dilution protocol | Inquiry |
| Incubation Stability and Transfection Evaluation | Reporter transfection assays, cellular uptake, endosomal escape, and intracellular localization across cell lines | Stability-performance correlation report; dose-response curves | Inquiry |
LNP stability for transfection studies is a workflow problem, not a single test. The LNP that delivers consistent transfection data is the LNP that has been verified at every step — a stable, well-characterized vial that thaws cleanly, holds its physical and chemical integrity through working-solution preparation, resists dilution-induced cargo leakage and protein-corona-driven aggregation, and retains its endosomal escape behavior in the specific medium and cell line being tested. A meaningful stability program applies the right test to the right stage: size, zeta potential, EE%, lipid purity, and payload integrity at storage; rapid post-thaw release checks before use; NTA and zeta in working medium after dilution; and reporter transfection, uptake, and endosomal escape at incubation. BOC Sciences supports each of these stages with orthogonal analytical methods, cell-based functional assays, and formulation optimization feedback loops — enabling research teams to translate stability data into more robust, reproducible transfection outcomes.
